Stay updated on Phase 1b Combo w/ Ribociclib & Alpelisib Clinical Trial
Sign up to get notified when there's something new on the Phase 1b Combo w/ Ribociclib & Alpelisib Clinical Trial page.

Latest updates to the Phase 1b Combo w/ Ribociclib & Alpelisib Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAn NIH website-transition announcement banner appears above the page, and the displayed site revision changes from v3.7.1 to v3.7.2. The study page continues to show a 403 error.SummaryDifference1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe site's footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedA 403 Forbidden error page is now displayed for the study record, with minimal HTML including a 403 title and a Home link.SummaryDifference20%

- Check48 days agoChange DetectedThe page now reflects a status of Active, not recruiting and No longer looking for participants. It also adds the Vanderbilt-Ingram Cancer Center and Kenneth Caldwell, MD as the study site and investigator and expands the study to four treatment groups.SummaryDifference4%

- Check62 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6. This appears to be a minor platform update with no apparent changes to study details or page content.SummaryDifference0.0%

- Check84 days agoChange DetectedThe page's revision indicator was updated from v3.6.4 to v3.6.5, indicating a small maintenance update. No user-facing content appears to be changed.SummaryDifference0.0%

Stay in the know with updates to Phase 1b Combo w/ Ribociclib & Alpelisib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1b Combo w/ Ribociclib & Alpelisib Clinical Trial page.